Inno-Gene S.A.

Equities

IGN

PLINNGN00015

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
1.76 ^PLN	0.00%		-1.68%	-20.00%

02-14	Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-14	Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 14, 2024 at 05:55 pm

Inno-Gene S.A. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was PLN 0.147 million compared to PLN 0.676 million a year ago. Net loss was PLN 0.148 million compared to PLN 0.351 million a year ago.

Latest news about Inno-Gene S.A.

Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding	01-10	CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	07/02/23	CI
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	07/02/23	CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Ignitis to Secure $119 Million Credit Line to Bolster Capital Amid Higher Energy Prices	25/10/22	MT
Naturativ Sp. z o.o. announced that it has received PLN 0.49995 million in funding from Inno-Gene S.A.	17/08/22	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
Inno-Gene S.A. acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million.	31/05/22	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Ignitis Expects Debt Repayment, Compensation as Lithuania Enacts Anti-Inflation Measures	04/04/22	MT
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	14/02/22	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	14/02/22	CI
Ignitis Grupé Unit Acquires Wind Farm in Poland	21/12/21	MT
Ignitis Secures Polish License to Operate Wind Farm	07/12/21	MT
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	15/05/21	CI
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	14/02/21	CI
CovidVax sp. Z oo announced that it expects to receive PLN 10 million in funding from Inno-Gene S.A.	05/10/20	CI
Inno-Gene S.A. acquired unknown stake in INNGEN SA for PLN 0.01 million.	19/08/20	CI

Chart Inno-Gene S.A.

Duration

Period

More charts

Company Profile

Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INNO-GENE S.A.	-20.00%	2.79M
GUARDANT HEALTH, INC.	-4.81%	3.15B
IOVANCE BIOTHERAPEUTICS, INC.	+31.37%	2.99B
BGI GENOMICS CO., LTD.	-14.73%	2.15B
VERACYTE, INC.	-14.39%	1.8B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+70.99%	1.49B
CAREDX, INC	+23.17%	770M
SEEGENE, INC.	-2.18%	762M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-20.41%	575M
CURIOX BIOSYSTEMS CO., LTD	+3.18%	308M

Bio Diagnostics & Testing